Bide Pharmatech Co. Ltd. A Working Capital to Net Assets Ratio
Bide Pharmatech Co. Ltd. A working capital to net assets ratio. Bide Pharmatech Co. Ltd. A (688073) has a Working Capital to Net Assets ratio of 96.7% as of March 2026. Working capital of CN¥2.03 Billion (current assets of CN¥2.35 Billion minus current liabilities of CN¥315.91 Million) is measured against net assets of CN¥2.10 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Bide Pharmatech Co. Ltd. A (2020–2025)
Working capital to net assets ratio of Bide Pharmatech Co. Ltd. A from 2020 to 2025. This chart shows how Bide Pharmatech Co. Ltd. A's Working Capital to Net Assets ratio has evolved across 6 annual periods from 2020 to 2025. As of March 2026, the ratio stands at 96.7%, reflecting working capital of CN¥2.03 Billion against net assets of CN¥2.10 Billion CNY. See how many days can Bide Pharmatech Co. Ltd. A fund operations to measure how many days the company can operate on defensive assets alone.
Bide Pharmatech Co. Ltd. A Working Capital to Net Assets Ratio by Year (2020–2025)
Bide Pharmatech Co. Ltd. A working capital to net assets ratio by year from 2020 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Bide Pharmatech Co. Ltd. A from 2020 to 2025, covering 6 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Bide Pharmatech Co. Ltd. A balance sheet assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 96.0% | CN¥1.96 Billion | CN¥2.05 Billion | CN¥2.30 Billion | CN¥341.82 Million | ▲ +4.1 pp |
| 2024 | 91.9% | CN¥1.86 Billion | CN¥2.03 Billion | CN¥2.21 Billion | CN¥345.76 Million | ▼ -3.2 pp |
| 2023 | 95.1% | CN¥1.99 Billion | CN¥2.09 Billion | CN¥2.26 Billion | CN¥274.97 Million | ▼ -1.1 pp |
| 2022 | 96.1% | CN¥2.00 Billion | CN¥2.08 Billion | CN¥2.24 Billion | CN¥249.07 Million | ▲ +5.8 pp |
| 2021 | 90.3% | CN¥568.15 Million | CN¥628.86 Million | CN¥817.71 Million | CN¥249.56 Million | ▲ +4.3 pp |
| 2020 | 86.0% | CN¥313.37 Million | CN¥364.26 Million | CN¥456.79 Million | CN¥143.42 Million | — |